**Pills more stable than liquid

[Guest guest]

http://www.geocities.com/~vera_b/alts/naltrexone.html

Naltrexone is a commercially avaliable prescription drug, approved by the FDA since the early 1980s, which is manufactured by DuPont and made available under the trade name of ReVia. It has been used for a number of years as an adjunct to the treatment of opioid addictions, and sometimes alcoholism as well. There has been off-label experimenation with this drug for other purposes, namely in the treatment of autism, obesity, and certain types of cancer.

Naltrexone blocks opioid receptors on the surface of cells. As a result, opiates will not produce euphoria and their effect on pain may be less predictable. It is thought that when very small doses are used, naltrexone will increase natural endorphins in the body which play a role not only in mood regulation but also in the level of immune functioning. Two physicians have experimented with the use of naltrexone in cancer: Dr Bihari in NYC, and Dr Margaret Lewin, an oncologist at New York Hospital-Cornell Medical Center. Dr Bihari looked for an opiod antagonist when he realized this could boost the immune functioning of his AIDS patients. When he got good results with it, he then postulated that certain cancers that have plenty of opioid receptors in their cells, could also be influenced by this drug. He suggested it in 1993 to Dr Lewin who has tried it in a few patients with lymphoma. Early research showed that heroin inhibits the growth of certain tumors, and that a certain endorphin called metenkephalin prolongs the survival of mice with leukemia, melanoma, and other cancers. Further research found that opiate receptors play a key role in the action of these endorphins. Naltrexone was used in these studies. Other studies showed that high doses of naltrexone stimulated tumor growth, and very small doses prolong survival in mice with cancer, and protect those mice at risk of developing cancer. It was noted that opiate peptides play a key role in regulating the growth of certain cancers, and then hypothesized that small daily doses of naltrexone would enhance the protective effect of endorphins by increasing the number and density of opiate receptors on tumor cells. The effects of the endorphins are thought to work against the cancer cells indirectly by inhibiting their DNA synthesis and mitosis, and other subtle changes. There is a significant body of literature that suggested to Dr Bihari that endorphins are very involved in the regulation of immune function, and led to his initial experimentation with HIV positive patients. He and his colleagues found that low dose naltrexone increases beta-endorphins in healthy volunteers within 2 hours, with a greater rise some 12-16 hours later if the dose was given in the late evening. Their 12 week placebo controlled trial in AIDS patients showed decline in the levels of alpha interferon and better protection against opportunistic infections (no patients of 22 in the active arm developed infections, while 5 of the 16 placebo arm patients did). Another placebo controlled trial showed a significant increase in NK (natural killer) cells, as well as lymphomcytes and CD4s. Dr Bihari thinks that naltrexone may work in the following ways: by increasing the endorphin levels, by increasing opiate receptors in tumor cell membranes and thus making the cells more susceptible to endorphin effects, and by increasing the levels of NK cells and their activity. The cancers thought most responsive to low dose naltrexone originate in tissues with high densities of opioid receptors, particularly lymphomas (including Hodgkin's disease, NHL, CLL, and multiple myeloma) and cancer of the pancreas. Other cancers also quite high in these receptors are colorectal cancers, metastatic melanoma, neuroblastoma, glioma, cancer of the small intestine, prostate cancer, and some endocrine cancers. Dr Bihari began to use naltrexone in cancer in 1985 in a patient with NH lymphoma that recurred and the patient refused further chemo. Her large groin tumors regressed within 12 weeks and she died 4 years later of an unrelated cause while still in remission. Dr Bihari introduced Dr Lewin to naltrexone in 1993, and she has apparently been using it in her practice with some cancer patients who have exhausted mainstream treatments. An indetermined percentage ("sizable minority") of these patients have had success with it, and Dr Lewin has been reported to say she considers the results "suggestive." She has not used it with untreated patients. ***Naltrexone for cancer is used at 3 mg per day, once a day, at bedtime. Since the drug only comes in 50 mg pills, a compounding pharmacy has to grind the pill down and make low dose pills. Dr Bihari feels that these pills are more stable than liquid made from the 50 mg pill. There are a number of pharmacies around the country that make it available. Check with your local compounding pharmacy,